Delayed-Release Metformin Formulations for Intestinal Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional metformin formulations cause significant gastrointestinal complications and systemic exposure risks, limiting their use in patients with contraindications such as kidney disorders, lung disease, and heart failure, and are not adequately addressed by extended-release formulations.
Innovation Solution
Development of delayed-release formulations that minimize systemic bioavailability of biguanide compounds like metformin, reducing gastrointestinal adverse effects and allowing treatment in contraindicated patient populations by targeting delivery to specific intestinal regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional metformin formulations are administered to patients, then therapeutic efficacy for lowering blood glucose is achieved, but gastrointestinal complications and systemic exposure risks increase significantly
Solution Approach 1:
The patent divides the gastrointestinal tract into different segments (proximal small intestine vs. distal small intestine/colon) and targets metformin delivery specifically to the distal segments. This segmentation allows the drug to exert therapeutic effects while minimizing exposure and harmful effects in the proximal segments where most absorption occurs.
Solution Approach 2:
The patent applies local quality by creating different drug release characteristics in different locations of the gastrointestinal tract. The delayed-release formulation ensures metformin is released and acts locally in the distal small intestine and colon, while minimizing systemic absorption and gastrointestinal side effects in other regions.
2Reliability
If conventional metformin formulations are administered to patients, then blood glucose lowering effect is achieved, but systemic bioavailability increases leading to lactic acidosis risk
Solution Approach 1:
By segmenting the gastrointestinal tract and targeting distal regions, the patent reduces overall systemic absorption of metformin. This segmentation strategy maintains local therapeutic effects while minimizing the amount of drug entering systemic circulation, thereby reducing lactic acidosis risk.
Solution Approach 2:
The delayed-release formulation acts as an intermediary mechanism that controls where and when metformin is released. This intermediary system ensures the drug reaches its site of action in the distal gastrointestinal tract while limiting excessive systemic absorption that would lead to harmful effects.
3Duration of action of moving object
If extended-release formulations are used, then duration of action is improved, but gastrointestinal tolerability is not adequately addressed
Solution Approach 1:
The patent applies local quality by specifically targeting the distal small intestine and colon for drug release, rather than simply extending the release duration throughout the entire gastrointestinal tract. This localized approach maintains prolonged action where needed while avoiding gastrointestinal tolerability issues in other regions.
Solution Approach 2:
Instead of only extending the time dimension (duration of action), the patent adds a spatial dimension by targeting specific locations in the gastrointestinal tract. This dimensional change allows the drug to maintain prolonged action while avoiding the gastrointestinal tolerability problems that plague conventional extended-release formulations.
4Object-affected harmful factors
If delayed-release formulations targeting distal intestinal regions are used, then gastrointestinal complications are reduced, but therapeutic efficacy must be maintained
Solution Approach 1:
The patent segments the gastrointestinal tract and targets the distal segments for drug release, which reduces gastrointestinal complications in the proximal regions while maintaining therapeutic efficacy in the target regions. This segmentation strategy resolves the contradiction by separating the site of harmful effects from the site of therapeutic action.
Solution Approach 2:
By applying local quality through site-specific drug release in the distal small intestine and colon, the patent maintains therapeutic efficacy at the target site while minimizing gastrointestinal complications in other regions. The local quality approach ensures the drug acts where needed without causing harm elsewhere.
Data Source
AI summary
Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.